Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharma Mar, S.A. (PHM.MC)
EUR75.80
-0.40 (-0.52%)
ES BME Healthcare Biotechnology
Address
Avenida de los Reyes, 1 28770
Madrid, ES
Madrid, ES
CEO
Jose Maria Fernandez Sousa-Faro
Website
pharmamar.com
IPO
2000-09-08
ISIN ES0169501022
Also trades on
London Stock Exchange · 0RC6.L (EUR)
Madrid Stock Exchange · PHM.MC (EUR)
Other OTC · PHMMF (USD)
Description
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR75.80
-0.40 (-0.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
89.8K
Beta
0.41
Float Shares
13.43M
Free Float %
77.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.69% | -6.33% | +5.06% | +28.59% | +30.48% | +30.31% | +29.36% | +173.08% | +18.79% | +247.58% | -53.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
75.80
DCF (Unlevered)
38.90
-48.7%
DCF (Levered)
12.93
-82.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
78% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
10.12
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%+26.6% ★ Q1'26: +10.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+192.6% ★ Q1'26: +138.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+21.4% Q1'26: +16.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+18.2% ★ Q1'26: +1.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+30.1% ★ Q1'26: +1.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.0% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.02× ★ Q1'26: 4.39× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
192.81M
est: 162.39M (+18.7%)
|
180.94M
est: 173.25M (+4.4%)
|
179.34M
est: 169.06M (+6.1%)
|
162.16M
est: 150.33M (+7.9%)
|
85.82M
est: 76.95M (+11.5%)
|
269.96M
est: 157.53M (+71.4%)
|
229.83M
est: 120.28M (+91.1%)
|
196.34M
est: 106.50M (+84.4%)
|
158.15M
est: 158.80M (-0.4%)
|
174.86M
est: 174.21M (+0.4%)
|
221.39M
est: 217.44M (+1.8%)
|
228.34M
204.65M – 316.47M
+5.0% YoY
|
324.21M
255.00M – 441.00M
+42.0% YoY
|
424.51M
424.51M – 424.51M
+30.9% YoY
|
423.84M
353.06M – 581.15M
-0.2% YoY
|
503.06M
419.05M – 689.76M
+18.7% YoY
|
| EBITDA |
14.23M
est: 46.96M (-69.7%)
|
-12.24M
est: 50.10M (-124.4%)
|
-12.99M
est: 48.89M (-126.6%)
|
-9.48M
est: 43.47M (-121.8%)
|
-11.71M
est: 22.25M (-152.6%)
|
155.94M
est: 45.55M (+242.3%)
|
104.09M
est: 34.78M (+199.3%)
|
52.07M
est: 30.80M (+69.1%)
|
4.55M
est: 34.50M (-86.8%)
|
21.23M
est: 37.85M (-43.9%)
|
48.30M
est: 47.24M (+2.2%)
|
49.61M
44.47M – 68.76M
+5.0% YoY
|
70.44M
55.40M – 95.82M
+42.0% YoY
|
92.23M
92.23M – 92.23M
+30.9% YoY
|
92.09M
76.71M – 126.27M
-0.2% YoY
|
109.30M
91.05M – 149.87M
+18.7% YoY
|
| EBIT |
11.30M
est: 41.89M (-73.0%)
|
-19.49M
est: 44.69M (-143.6%)
|
-19.60M
est: 43.61M (-145.0%)
|
-15.85M
est: 38.78M (-140.9%)
|
-17.77M
est: 19.85M (-189.5%)
|
148.73M
est: 40.63M (+266.0%)
|
98.50M
est: 31.02M (+217.5%)
|
46.17M
est: 27.47M (+68.1%)
|
-1.21M
est: 29.24M (-104.1%)
|
14.45M
est: 32.08M (-54.9%)
|
40.28M
est: 40.04M (+0.6%)
|
42.04M
37.68M – 58.27M
+5.0% YoY
|
59.70M
46.95M – 81.20M
+42.0% YoY
|
78.17M
78.17M – 78.17M
+30.9% YoY
|
78.04M
65.01M – 107.01M
-0.2% YoY
|
92.63M
77.16M – 127.01M
+18.7% YoY
|
| Net Income |
6.59M
est: 15.44M (-57.3%)
|
-24.08M
est: -13.35M (-80.4%)
|
-26.75M
est: -16.44M (-62.7%)
|
-5.54M
est: -8.43M (+34.3%)
|
-9.18M
est: -30.03M (+69.4%)
|
137.26M
est: 137.06M (+0.1%)
|
92.86M
est: 56.57M (+64.1%)
|
49.36M
est: 50.33M (-1.9%)
|
1.14M
est: -1.76M (+164.6%)
|
26.13M
est: 19.90M (+31.3%)
|
74.99M
est: 60.88M (+23.2%)
|
57.32M
20.04M – 87.54M
-5.8% YoY
|
133.67M
69.81M – 196.97M
+133.2% YoY
|
218.13M
93.87M – 276.67M
+63.2% YoY
|
214.48M
167.92M – 317.96M
-1.7% YoY
|
278.03M
217.67M – 412.17M
+29.6% YoY
|
| SGA |
68.60M
est: 25.16M (+172.7%)
|
68.02M
est: 26.84M (+153.4%)
|
65.50M
est: 26.19M (+150.1%)
|
59.25M
est: 23.29M (+154.4%)
|
37.82M
est: 11.92M (+217.2%)
|
35.77M
est: 24.41M (+46.6%)
|
39.74M
est: 18.63M (+113.3%)
|
43.24M
est: 16.50M (+162.1%)
|
41.81M
est: 28.91M (+44.6%)
|
-2.68M
est: 31.72M (-108.4%)
|
59.38M
est: 39.59M (+50.0%)
|
41.57M
37.26M – 57.62M
+5.0% YoY
|
59.03M
46.43M – 80.29M
+42.0% YoY
|
77.29M
77.29M – 77.29M
+30.9% YoY
|
77.17M
64.28M – 105.81M
-0.2% YoY
|
91.59M
76.30M – 125.59M
+18.7% YoY
|
| EPS |
0.36
est: 0.88 (-59.1%)
|
-1.31
est: -0.76 (-72.3%)
|
-1.45
est: -0.94 (-54.9%)
|
-0.30
est: -0.48 (+37.5%)
|
-0.50
est: -1.71 (+70.8%)
|
7.50
est: 7.80 (-3.9%)
|
5.14
est: 3.22 (+59.6%)
|
2.73
est: 2.87 (-4.7%)
|
0.06
est: -0.10 (+163.2%)
|
1.49
est: 1.02 (+46.0%)
|
4.36
est: 3.12 (+39.6%)
|
2.63
1.16 – 5.09
-15.7% YoY
|
6.78
4.06 – 11.44
+157.5% YoY
|
11.34
5.45 – 16.08
+67.4% YoY
|
12.46
9.76 – 18.48
+9.9% YoY
|
16.16
12.65 – 23.95
+29.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
53.62M
OE per share TTM
3.10
Owner's Yield
3.01%
Maintenance CapEx ratio
4.48%
Maint CapEx / Avg PPE
21.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 89 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Aging Population ETF AGNG | 0.25% | 212.7K | 0.50% |
| 2 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc WTIM.DE | 0.22% | 124.0K | 0.29% |
| 3 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR EGRW.L | 0.22% | 124.0K | 0.29% |
| 4 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.21% | 1.56M | 0.33% |
| 5 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.20% | 2.08M | 0.58% |
| 6 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.13% | 1.47M | 0.40% |
| 7 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.12% | 110.9K | 0.38% |
| 8 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.12% | 110.9K | 0.38% |
| 9 | Xtrackers Spain UCITS ETF 1C XESP.DE | 0.12% | 356.3K | 0.30% |
| 10 | Xtrackers Spain UCITS ETF 1D XESD.DE | 0.12% | 356.3K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
80.6K
Shares Outstanding
17.31M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jose Maria Fernandez Sousa-Faro | Founder, Executive Chairman, Chief Executive Officer & President | 294.0K | male |
| Pedro Francisco Fernandez Puentes | Executive Vice-Chairman | 124.0K | male |
| Juan Carlos-Torres Carretero | Founder | — | male |
| Juan Gomez Pulido | General Counsel & Secretary of the Board of Directors | — | male |
| Lara Vadillo | Communication Director | — | female |
| Luis Rupérez Cuenca | Director of Human Resources & IT | — | male |
| María Luisa de Francia Caballero | Chief Financial Officer | — | female |
| Belén Sopesén Veramendi | Director of Corporate Development | — | female |
| Sandra Llamera Sanchez | Global Compliance Head | — | female |
| José Luis Moreno Martinez-Losa | Head of Capital Markets & Investor Relations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHM.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
